Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

The miss triggered target cuts alongside a securities investigation into prior comments.

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

Upstream Bio Sets Phase 3 Start for Verekitug in Severe Asthma and Nasal Polyps

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Cosmo’s Clascoterone Meets Phase III Goals in Male-Pattern Baldness Trials

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Regeneron’s Garetosmab Slashes New Bone Lesions in FOP Phase 3, U.S. Filing Planned This Year

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement

New Non-Hormonal Drug Shows Promise for Menopausal Hot Flashes